Lucerna Wealth Management is a private-limited-guarant-nsc company established in 1994, operating from the Society of Antiquaries of London, Piccadilly, W1J 0BE. Currently, Lucerna is active and maintains a strong regulatory status with registration number 02906521. The company’s core business focuses on the development and provision of specialized research tools and services, primarily centered around RNA-targeted drug discovery. Lucerna specializes in providing advanced technologies and methodologies to accelerate the research process within the pharmaceutical industry. We offer a range of tools designed to enhance the identification, validation, and optimization of RNA-based therapeutics. The company’s expertise spans the entire lifecycle of RNA research, from initial target identification to preclinical and clinical trial support. Lucerna’s strategic focus is on supporting RNA-driven innovation, aiming to provide a competitive advantage to clients through enhanced research capabilities. The company’s international presence is currently limited, with operations primarily concentrated within the United Kingdom. Lucerna employs a significant number of skilled workers, indicating a commitment to ongoing investment in research and development. The company’s SIC codes include -91030, reflecting its involvement in historical site and building-related activities and visitor attractions.

Lucerna Wealth Management is a private-limited-guarant-nsc company established in 1994, operating from the Society of Antiquaries of London, Piccadilly, W1J 0BE. Currently, Lucerna is active and maintains a strong regulatory status with registration number 02906521. The company’s core business focuses on the development and provision of specialized research tools and services, primarily centered around RNA-targeted drug discovery. Lucerna specializes in providing advanced technologies and methodologies to accelerate the research process within the pharmaceutical industry. We offer a range of tools designed to enhance the identification, validation, and optimization of RNA-based therapeutics. The company’s expertise spans the entire lifecycle of RNA research, from initial target identification to preclinical and clinical trial support. Lucerna’s strategic focus is on supporting RNA-driven innovation, aiming to provide a competitive advantage to clients through enhanced research capabilities. The company’s international presence is currently limited, with operations primarily concentrated within the United Kingdom. Lucerna employs a significant number of skilled workers, indicating a commitment to ongoing investment in research and development. The company’s SIC codes include -91030, reflecting its involvement in historical site and building-related activities and visitor attractions.